# Lightswitch Capital

> Lightswitch Capital is a VC fund in New York backing Life Science and Biotechnology. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 5
- Last investment: Jan 2025
- Lead investor: 20%
- Last updated: Aug 2026
- Website: https://www.lightswitchcap.com

Lightswitch Capital is a venture capital firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Life Science | 2 | 40% |
| Biotechnology | 2 | 40% |
| Medical | 1 | 20% |
| Biopharma | 1 | 20% |
| Neuroscience | 1 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 40% |
| Series A | 1 | 20% |
| Series B | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Hinge Bio | Hinge Bio is a biotechnology company that specializes in leveraging its proprietary Flex-Hinge antibody platform to develop bispecific and multispecific antibodies. It features chemical ligation process technology that enables the production of therapeutic candidates with orders-of-magnitude improved affinity and specificity.The company wasfounded in 2015 and headquartered in Burlingame, California. | $30M | Series A | Jan 15, 2025 |  |
| Alto Neuroscience | Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. | $45M | Series C | Nov 21, 2023 |  |
| Alto Neuroscience | Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. | $45M | Series C | Nov 21, 2023 |  |
| Alto Neuroscience | Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. | $35M | Series B | Oct 25, 2022 |  |
| Kriya Therapeutics | Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. | $270M | Series C | May 16, 2022 |  |

5 of 5 investments shown.

## Co-investors
- [Alkeon Capital](https://shizune.co/investors/profile/alkeon-capital) — VC Fund, 3 deals together
- [InVivium Capital](https://shizune.co/investors/profile/invivium-capital) — VC Fund, 3 deals together
- [What If Ventures](https://shizune.co/investors/profile/what-if-ventures) — VC Fund, 3 deals together
- [Windham Venture Partners](https://shizune.co/investors/profile/windham-venture-partners) — VC Fund, 3 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 2 deals together
- [Alpha Wave Ventures](https://shizune.co/investors/profile/alpha-wave-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Lightswitch Capital invest in?

Lightswitch Capital invests primarily in Life Science, Biotechnology and Medical startups, most often at Series C and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Lightswitch Capital last invest?

The most recent investment recorded for Lightswitch Capital closed in Jan 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co